Abstract:Chronic obstructive pulmonary disease (COPD) is characterized by lung extracellular matrix (ECM) remodeling that contributes to obstruction. This is driven, in part by extracellular vesicles (EVs) from activated neutrophils (PMNs), which express on their surface an α-1 antitrypsin (AAT) insensitive form of neutrophil elastase (NE). These EVs are predicted to bind to collagen fibers via Mac-1 integrins, during which time NE can enzymatically degrade the collagen. Protamine sulfate (PS), a cationic compound used safely for decades in humans, has been shown, in vitro, to dissociate this NE from the EV surface, rendering it AAT-sensitive. In addition, a nonapeptide inhibitor, MP-9, has been shown to prevent EV association with collagen. We sought to test whether PS, MP-9, or a combination of the two could effectively prevent NE+ EV-driven ECM remodeling in an animal COPD model. EVs were preincubated with PBS, protamine sulfate (25 μM), MP-9 (50 μM), or a combination of PS and MP-9. These were delivered intratracheally to anesthetized female 10- to 12-wk-old A/J mice for a 7-day time period. One group of mice was euthanized and lungs sectioned for morphometry, and the other group was used for live pulmonary function testing. The effect of alveolar destruction by activated neutrophil EVs was abrogated by pretreatment with PS or MP-9. However, in pulmonary function tests, only the PS groups (and combined PS/MP-9 groups) returned pulmonary function to near-control levels. These data presented here offer an insight into the effective use of PS in therapeutic setting for EV-derived alveolar damage.NEW & NOTEWORTHY Protamine sulfate facilitates the removal of neutrophil elastase (NE) from the surface of extracellular vesicles from activated neutrophils. This "free" NE is no longer protected from inhibition by its endogenous anti-protease, α-1-anti-trypsin. This function of protamine sulfate highlights it as a potential therapeutic strategy for COPD, which may attenuate the disease process.

Targeting neutrophil serine proteases in bronchiectasis

Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target

Neutrophil elastase in bronchiectasis

Neutrophil Elastase and Chronic Lung Disease

Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study

Old Players and New Prospects

Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study

Airway Acidification Impaired Host Defense Against Pseudomonas Aeruginosa Infection by Promoting Type 1 Interferon Β Response

Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease

Rethinking bronchiectasis as an inflammatory disease

Targeting Proteases in Cystic Fibrosis Lung Disease: Paradigms, Progress, and Potential.

Angiotensin-converting Enzyme Defines Matrikine-Regulated Inflammation and Fibrosis

Our evolving view of neutrophils in defining the pathology of chronic lung disease

Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease

Reasearch Progress on the Role of Neutrophils in Asthma

Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis

Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases)

Neutrophil dynamics in pulmonary fibrosis: pathophysiological and therapeutic perspectives

Neutrophil elastase promotes macrophage cell adhesion and cytokine production through the integrin-Src kinases pathway

Clinical perspectives in bronchiectasis management

Therapeutic effect of two strategies directed at disruption of pathogenic neutrophil extracellular vesicles in a murine emphysema model